Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

This study is testing a new drug called HG146 (an HDAC inhibitor) in people with adenoid cystic carcinoma — a rare type of cancer that most often appears in salivary glands, but can also occur in other parts of the head, neck, breast, or trachea. The drug aims to slow or stop cancer growth by blocking proteins that help cancer cells survive. **You may be eligible if...** - You are 18 or older - You have recurrent or metastatic adenoid cystic carcinoma that has progressed within the past year - You have at least one measurable tumor - You are in good general health (ECOG 0–1) - Your organs (heart, liver, kidneys) are functioning adequately **You may NOT be eligible if...** - You have brain metastases requiring steroids - You have previously been treated with an HDAC-targeting drug - You received chemotherapy or other anti-cancer therapy within 3–4 weeks before starting this study Talk to your doctor to see if this trial is right for you.